Does the supplementation of vitamin D affect depressive symptoms?

2016 ◽  
Vol 33 (S1) ◽  
pp. S414-S414
Author(s):  
P. Kolarov ◽  
M. Stoimenova
Keyword(s):  
Vitamin D ◽  
Depressive Symptoms ◽  
Vitamin D3 ◽  
Well Being ◽  
Vitamin D Supplementation ◽  
High Dose ◽  
Vitamin D Levels ◽  
Competing Interest ◽  
Development Course ◽  
Course Of Depression

IntroductionDepression has been linked to decreased levels of vitamin D in adults and the altered dietary intake of calcium and vitamin D has been reported to have implications for the development of depressive symptoms. Although, the relation between vitamin D and depression has been established, it is not yet clear whether the supplementation of vitamin D could affect the clinical manifestation of depression. Therefore, the aim of this study was to determine whether the supplementation of vitamin D could affect the development/course of depression.Material and methodsA systematic literature search was performed for randomized control trials (RCTs) in which vitamin D was supplemented and depression was measured.Results and discussionSix studies were identified as being eligible to be included in this review. The results regarding the supplementation of vitamin D and its effect on the course and manifestation of depression were conflicting. One study concluded that the supplementation of vitamin D3 had beneficial effect in depression and another study reported no improvement in the indices of mental well-being in the vitamin D supplemented group and rejected the hypothesis that an annual high dose of vitamin D3 could prevent depressive symptoms. The remainder four studies reported inconclusive results regarding vitamin D supplementation and the course of depression.ConclusionAs current literature displayed contradictory results and no sound conclusion could be drawn regarding the supplementation of vitamin D and its effect on depression, there is a need of RCTs to determine whether the supplementation of vitamin D levels could affect depression.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals Design and Main Results of STURDY: A Randomized Clinical Trial of Four Vitamin D3 Doses to Prevent Falls in Older Adults

2020 ◽  
Vol 4 (Supplement_1) ◽  
pp. 759-759
Author(s):  
Lawrence Appel ◽  
Jennifer Schrack ◽  
Erin Michos ◽  
Christine Mitchell ◽  
Stephen Juraschek ◽  
...  
Keyword(s):  
Vitamin D ◽  
Vitamin D3 ◽  
Primary Outcome ◽  
Vitamin D Supplementation ◽  
Dose Finding ◽  
High Dose ◽  
Hazard Ratios ◽  
Risk Of Falls ◽  
Event Rates ◽  
And Control

Abstract STURDY was a Bayesian, response-adaptive trial with dose-finding and confirmatory stages. Participants (n=688; ≥70years with serum 25(OH)D of 10-29ng/mL) were randomized to 200 (control), 1000, 2000, or 4000 IU/day of vitamin D3. The primary outcome was time to first fall or death over 2 years. During dose-finding, the best non-control dose was determined to be 1000IU/day based on higher primary outcome event rates in the 2000 and 4000IU/day doses than the 1000IU/day dose (posterior probability of being best dose=0.90; hazard ratios[HR] were 1.86 [95%CI: 1.16-2.97] and 1.68 [95%CI: 1.05-2.69], respectively). Participants were then switched from other non-control doses to 1000IU/day, and event rates did not differ between the pooled higher doses and control groups (HR=1.02, P=0.84). There was no heterogeneity by baseline 25(OHD). In conclusion, high-dose vitamin D supplementation ≥1000IU/day did not prevent falls. Whether vitamin D doses >2000IU/day increase the risk of falls is uncertain.

scholarly journals Vitamin D and Atherosclerotic Cardiovascular Disease

2019 ◽  
Vol 104 (9) ◽  
pp. 4033-4050 ◽  
Author(s):  
Thomas F Hiemstra ◽  
Kenneth Lim ◽  
Ravi Thadhani ◽  
JoAnn E Manson
Keyword(s):  
Cardiovascular Disease ◽  
Vitamin D ◽  
General Population ◽  
Vitamin D Deficiency ◽  
Randomized Trials ◽  
Cardiovascular Health ◽  
Vitamin D Supplementation ◽  
High Dose ◽  
Atherosclerotic Cardiovascular Disease ◽  
Vitamin D Levels

Abstract Context A large body of experimental and observational data has implicated vitamin D deficiency in the development of cardiovascular disease. However, evidence to support routine vitamin D supplementation to prevent or treat cardiovascular disease is lacking. Design and Results A comprehensive literature review was performed using PubMed and other literature search engines. Mounting epidemiological evidence and data from Mendelian randomization studies support a link between vitamin D deficiency and adverse cardiovascular health outcomes, but randomized trial evidence to support vitamin D supplementation is sparse. Current public health guidelines restrict vitamin D intake recommendations to the maintenance of bone health and prevention of fractures. Two recently published large trials (VITAL and ViDA) that assessed the role of moderate- to high-dose vitamin D supplementation as primary prevention for cardiovascular outcomes in the general population had null results, and previous randomized trials have also been generally negative. These findings from general population cohorts that are largely replete in vitamin D may not be applicable to chronic kidney disease (CKD) populations, in which the use of active (1α-hydroxylated) vitamin D compounds is prevalent, or to other high-risk populations. Additionally, recent trials in the CKD population, as well as trials using vitamin D analogs, have been limited. Conclusions Current randomized trials of vitamin D supplementation do not support benefits for cardiovascular health, but the evidence remains inconclusive. Additional randomized trials assessing larger numbers of participants with low baseline vitamin D levels, having longer follow-up periods, and testing higher vitamin D dosages are needed to guide clinical practice.

scholarly journals Effect of Vitamin-D supplementation in adults presenting with chronic lower back pain

2020 ◽  
Vol 24 (2) ◽  
pp. 161-165
Author(s):  
Rahman Rasool Akhtar ◽  
Riaz Ahmed ◽  
Sabeen Ashraf ◽  
Omair Ashraf ◽  
Umer Shafique ◽  
...  
Keyword(s):  
Vitamin D ◽  
Back Pain ◽  
Pain Score ◽  
Lower Back Pain ◽  
Vitamin D3 ◽  
Vitamin D Supplementation ◽  
Chronic Lower Back Pain ◽  
Oral Vitamin ◽  
Lower Back ◽  
Vitamin D Levels

Background: Chronic pain in the lower back of adults is a common problem and mostly associated with Vitamin D deficiency. Along with standard treatment, vitamin D supplementation can help in early and better relief from back pain. Objective: To assess the effectiveness of vitamin D supplementation in patients with chronic lower back pain. Study Design & Methods: This Quasi-experimental trial was conducted at Department of Orthopaedics, Benazir Bhutto Hospital for 6 months. The patients aged between 15 to 55 years with chronic low back pain were included and pain score was noted by using a visual analogue scale (VAS). Patients were prescribed with oral vitamin D3 with a dose of 50,000 IU weekly for eight weeks (induction phase) and oral vitamin D3 with a dose of 50,000 IU once monthly for 6 months (maintenance phase). Outcome parameters included pain measured by VAS, functional disability by modified Oswestry disability questionnaire scores, and Vitamin-D3 levels at baseline,2, 3 and 6 months post-supplementation. Results: Mean age of patients was 44.21± 11.92 years.There were 337 (56.2%) male patients while 263 (43.8%) female patients. Baseline mean vitamin-D levels were 13.32 ± 6.10 ng/mL and increased to 37.18 ± 11.72 post supplementation (P < 0.0001). There was a significant decrease in the pain score after 2nd, 3rd& 6th months (61.7 ± 4.8, 45.2 ± 4.6 & 36.9 ± 7.9, respectively) than 81.2 ± 2.4 before supplementation (P < 0.001). The modified Oswestry disability score also showed significant improvement after 2nd, 3rd& 6thmonths (35.5 ± 11.4, 30.2 ± 9.4 & 25.8 ± 10.6, respectively) as compared to baseline 46.4 ± 13.2 (P < 0.001). About 418 (69.7%) patients attained normal levels after 6 months. Conclusion: Prescription of Vitamin D in addition to standard therapy for chronic lower back pain can be beneficial in getting relief from pain and improving the functional ability of the patient.

scholarly journals Vitamin D sebagai Terapi Potensial Anak Gizi Buruk

2019 ◽  
Vol 1 (1) ◽  
pp. 61-70
Author(s):  
Lisa Dwi Aryani ◽  
Muhammad Aldy Riyandry
Keyword(s):  
Vitamin D ◽  
Literature Review ◽  
Vitamin D Deficiency ◽  
Vitamin D3 ◽  
Child Nutrition ◽  
Infant Health ◽  
Well Being ◽  
High Dose ◽  
Z Score ◽  
The Impact

Masalah malnutrisi (gizi buruk) masih menjadi isu kesehatan global. Gizi buruk merupakan penyebab kematian tertinggi anak di negara berkembang. Malnutrisi adalah keadaan kekurangan energi dan protein berat akibat ketidakseimbangan antara ambilan makanan dengan kebutuhan gizi. Keadaan malnutrisi energi-protein sering dikaitkan dengan temuan kasus defisiensi vitamin D. Berdasarkan studi epidemiologi >50% anak malnutrisi berat juga mengalami defisiensi vitamin D. Pengoreksian melalui diet terapeutik sebagai standar pengobatan hanya mengandung vitamin D dalam jumlah sedang sehingga tidak cukup adekuat untuk mencukupi kebutuhan anak. Pemberian tambahan vitamin D3 dosis tinggi sebanyak 200.000 IU (5 mg) diduga mampu mengoreksi keadaan gizi buruk dengan meningkatkan berat badan dan nilai z-score anak. Literature review ini bertujuan untuk menjelaskan pengaruh pemberian vitamin D dalam memperbaiki tampilan klinis anak gizi buruk. Metode yang digunakan dalam artikel ini adalah penelusuran artikel melalui database NCBI dan Google Scholar. Tahun penerbitan sumber pustaka adalah dari tahun 2004 hingga 2019 dengan 29 sumber pustaka. Tema dalam artikel yang dikumpulkan yaitu terkait gambaran pengaruh pemberian vitamin D dalam meningkatkan berat badananak gizi buruk. Hasil dari sintesa 24 artikel yang telah ditemukan terdapat pengaruh pemberian vitamin D (cholecalciferol) terhadap kenaikan berat badan sebagai hasil kumulatif lemak di jaringan adiposa sehingga cukup potensial sebagai terapi gizi buruk.   Kata kunci: Vitamin D, gizi buruk, berat badan, cholecalciferol   VITAMIN D AS POTENTIAL THERAPY FOR MALNUTRITION CHILD   ABSTRACT Malnutrition (malnutrition) is still a global health problem. Malnutrition is the highest cause of deaths children in developing countries. Malnutrition is the impact of lack of energy and protein due to an imbalance between food intake and nutritional needs. The symptoms are marasmus, kwashiorkor or marasmik-kwashiorkor. Energy-protein malnutrition is often related to the case finding of vitamin D deficiency, which is caused by epidemiological studies>50% of severely malnourished children also have vitamin D deficiency. Correcting malnutrition with a therapeutic diet as a standard is sufficient to meet the child's needs. An additional 200,000 IU (5 mg) of high-dose vitamin D3 supplements can replace malnutrition by increasing the child's weight and z-score. This review summarizes the role of vitamin D as a potential therapy in improving infant health and well-being and malnutrition. The method taken by the article was made using the literature review method, involving 29 books, national or international journals. The results of a review of 24  articles that show the difference between vitamin D (cholecalciferol) and weight gain as a result of cumulative fat in adipose tissue through increased intracellular calcium, is quite potentially used as a supplementary therapy for child nutrition.   Keywords: vitamin D, malnutrition, weight, cholecalciferol

scholarly journals Vitamin D and COVID-19: evidence and recommendations for supplementation

2020 ◽  
Vol 7 (12) ◽  
pp. 201912
Author(s):  
George Griffin ◽  
Martin Hewison ◽  
Julian Hopkin ◽  
Rose Kenny ◽  
Richard Quinton ◽  
...  
Keyword(s):  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Experimental Models ◽  
Vitamin D Supplementation ◽  
Hospitalized Patients ◽  
Lung Damage ◽  
High Dose ◽  
Vitamin D Levels ◽  
Immune Health ◽  
The Uk

Vitamin D is a hormone that acts on many genes expressed by immune cells. Evidence linking vitamin D deficiency with COVID-19 severity is circumstantial but considerable—links with ethnicity, obesity, institutionalization; latitude and ultraviolet exposure; increased lung damage in experimental models; associations with COVID-19 severity in hospitalized patients. Vitamin D deficiency is common but readily preventable by supplementation that is very safe and cheap. A target blood level of at least 50 nmol l −1 , as indicated by the US National Academy of Medicine and by the European Food Safety Authority, is supported by evidence. This would require supplementation with 800 IU/day (not 400 IU/day as currently recommended in UK) to bring most people up to target. Randomized placebo-controlled trials of vitamin D in the community are unlikely to complete until spring 2021—although we note the positive results from Spain of a randomized trial of 25-hydroxyvitamin D3 (25(OH)D3 or calcifediol) in hospitalized patients. We urge UK and other governments to recommend vitamin D supplementation at 800–1000 IU/day for all, making it clear that this is to help optimize immune health and not solely for bone and muscle health. This should be mandated for prescription in care homes, prisons and other institutions where people are likely to have been indoors for much of the summer. Adults likely to be deficient should consider taking a higher dose, e.g. 4000 IU/day for the first four weeks before reducing to 800 IU–1000 IU/day. People admitted to the hospital with COVID-19 should have their vitamin D status checked and/or supplemented and consideration should be given to testing high-dose calcifediol in the RECOVERY trial. We feel this should be pursued with great urgency. Vitamin D levels in the UK will be falling from October onwards as we head into winter. There seems nothing to lose and potentially much to gain.

Vitamin D levels during and after high-dose vitamin D supplementation in women with early-stage breast cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e20561-e20561
Author(s):  
Q. J. Khan ◽  
B. F. Kimler ◽  
P. Sharma ◽  
P. S. Reddy ◽  
S. Baxa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Vitamin D3 ◽  
Early Stage ◽  
Linear Regression Analysis ◽  
Musculoskeletal Symptoms ◽  
High Dose ◽  
25Ohd Level ◽  
Vitamin D Levels ◽  
High Dose Vitamin

e20561 Background: Experts define vitamin D deficiency as a 25-hydroxyvitamin D (25OHD) level of < 20 ng/ml; a level < 32 ng/ml is considered insufficient for bone health and > 40 ng/ml may be associated with optimum musculoskeletal function and reduced risk for breast cancer. We conducted a study to determine the effect of high dose vitamin D3 at 50,000 IU/wk (HD vitD) on musculoskeletal symptoms from adjuvant letrozole in breast cancer patients. We present here the effectiveness of HD vitD in achieving optimum 25OHD levels and the rate of decline of 25OHD levels after 12 weeks of HD vitD. Methods: The cohort included post-menopausal women with early stage hormone receptor positive breast cancer initiating letrozole treatment. Women with baseline 25OHD levels < 40 ng/ml received 12 weeks of HD vitD. 25OHD levels were assessed at 6 and 12 weeks during HD vitD supplementation and at 3 and 6 months after completing HD vitD but while taking maintenance dose of 600–1000 IU of vitamin D3 daily. Results: 40 women that received HD vitD completed the follow-up phase of the study and are included in this analysis. At entry on study, median 25OHD level was 23 ng/ml; 38% of the women had vitD deficiency, 75% had insufficiency, and 93% had 25OHD levels < 40 ng/ml. Six weeks of HD vitD increased median 25OHD level to 60 ng/ml and another 6 weeks increased it further to 66 ng/ml. With only 6 weeks of HD vitD supplementation, 98% of the women achieved a 25OHD level of > 40 ng/ml. Median 25OHD levels 3 and 6 months after completion of HD vitD were 49 and 40 ng/ml, respectively. The median rate of decrease in vitD levels per month was 6.8% of the level at completion of supplementation. Using linear regression analysis, projected changes in 25OHD levels were calculated for each subject. Median extrapolated time to drop to a 25OHD level of < 40 ng/ml was 6.0 months, to <32 ng/ml was 7.8 months, and to <20 ng /ml was 10.6 months. Conclusions: Supplementation with vitD3 at 50,000 IU/week for 6 weeks is sufficient to achieve a 25OHD level of >40 ng/ml in 98% of postmenopausal women with breast cancer on an AI. After 12 weeks of HD vitD, there is a steady decline in 25OHD levels at a rate of about 7% per month despite continuing on 600 to 1000 IU of D3 daily. Thus, standard doses of D3 are not adequate to maintain 25OHD levels achieved by HD vitD. No significant financial relationships to disclose.

A pilot study of the immunological effects of high-dose vitamin D in healthy volunteers

2012 ◽  
Vol 18 (12) ◽  
pp. 1797-1800 ◽  
Author(s):  
Aideen C Allen ◽  
Siobhan Kelly ◽  
Sharee A Basdeo ◽  
Katie Kinsella ◽  
Keith J Mulready ◽  
...  
Keyword(s):  
Vitamin D ◽  
Pilot Study ◽  
Mononuclear Cells ◽  
Vitamin D Supplementation ◽  
High Dose ◽  
Clinical Effects ◽  
Peripheral Blood Mononuclear ◽  
Reduced Frequency ◽  
Vitamin D Levels ◽  
25 Oh Vitamin D

Although vitamin D deficiency is considered an environmental factor in multiple sclerosis (MS), the immunological and clinical effects of vitamin D supplementation remain unclear. We performed a pilot study of the immunomodulatory effects of vitamin D in healthy individuals ( n=4), who took 5000–10,000 IU/day of vitamin D over 15 weeks. After 15 weeks of vitamin D supplementation, serum 25(OH) vitamin D levels rose significantly from baseline, with a corresponding increase in IL-10 production by peripheral blood mononuclear cells and a reduced frequency of Th17 cells. These data provide a strong rationale for randomised trials to assess the clinical effects of vitamin D supplementation in MS.

The use of vitamin D3 sublingual tablets versus oral drops in the treatment of patients with COMT Val/Val genotype and major depressive disorder

2017 ◽  
Vol 41 (S1) ◽  
pp. S730-S730
Author(s):  
A.W. Mech
Keyword(s):  
Vitamin D ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Vitamin D3 ◽  
Dopamine Synthesis ◽  
Major Depressive ◽  
Comt Genotype ◽  
Double Blind ◽  
Vitamin D Levels ◽  
Competing Interest

IntroductionVitamin D has been shown to be crucial in the regulation of dopamine and its relationship to major depressive disorder.A five-year pre-interventional study of 25 hydroxy vitamin D levels in patients with major depressive disorder found values ranging from 17 to 32 ng/mL.COMT Val/Val genotype has been associated with a 20–40% more rapid breakdown of dopamine in the prefrontal cortex as compared to individuals with a Val/Met genotype.MethodsThis retrospective study gathered data concerning outcome measurements in patients who displayed a baseline 25-OH level < 30 mg/mL and initially treated with sublingual tablet form of 10,000 IU vitamin D3. These data were compared to post interventional depression outcome scores for patients switched to oral vitamin D3 drops at a dose of 10,000 IUs.ResultsScores on the MADRS 1–3 weeks following the vitamin D3 switch showed an improvement in mood with the lowering of scores on the MADRS.ConclusionsPatients with a COMT genotype of Val/Val showed clinical improvement with a switch from oral D3 sublingual tablets to oral D3 drops. Further studies are needed to draw from conclusions. Pre- and post-25-OH vitamin D levels and other dopamine synthesis variables including serum ferritin would be useful as well as prospective double-blind placebo controlled trials. The future use of genotype-specific and supportive approaches deserves serious investigation.Disclosure of interestThe author has not supplied his/her declaration of competing interest.

scholarly journals Changes in vitamin D levels and depressive symptoms in later life in England

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Giorgio Di Gessa ◽  
Jane P. Biddulph ◽  
Paola Zaninotto ◽  
Cesar de Oliveira
Keyword(s):  
Vitamin D ◽  
Depressive Symptoms ◽  
Later Life ◽  
Vitamin D Supplementation ◽  
Cross Sectional ◽  
Logistic Regression Models ◽  
Representative Study ◽  
Increased Risk ◽  
Vitamin D Levels

AbstractInadequate vitamin D levels have been associated with increased risk of depression. However, most of these studies are cross-sectional and failed to investigate the effect of changes in vitamin D levels. This study aimed to investigate the longitudinal association of changes in serum 25-hydroxyvitamin D levels with depressive symptoms in 3365 participants of the English Longitudinal Study of Ageing, a large nationally-representative study of older adults. Based on their vitamin D levels at baseline and follow-up (sufficient ≥ 50 nmol/L; insufficient < 50 nmol/L), participants were classified as follows: with sufficient levels at both waves; with sufficient levels at baseline but not at follow-up; with insufficient levels at baseline but ≥ 50 nmol/L at follow-up; and with levels < 50 nmol/L at each time point. Depressive symptoms were measured using the 8-point CES-D scale. Data were analysed using logistic regression models. Compared with those with sufficient levels of vitamin D at both waves, only those with insufficient levels throughout were more likely to report elevated depressive symptoms (OR = 1.39, 95% CI = 1.00–1.93). Becoming or no longer being vitamin D deficient was, in the short term, not associated with elevated depressive symptoms. Further evidence is required on whether vitamin D supplementation might contribute to the prevention or treatment of depression as well as on the duration of time for changes in vitamin D levels to lead to detectable changes in depressive symptoms.

Sign in / Sign up

Export Citation Format

Share Document